9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [10]
In the citing paper
“All recommend SGLT2 inhibition for patients with T2DM and eGFR as low as 30 mL/min/1.73 m2, particularly if severely increased albuminuria is present.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“Major national and international organizations are rapidly updating recommendations and guidelines (Table 4) (85–88).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“In the US, the 2020 national median drug acquisition cost of GLP-1RAs ranges from $634 per month to $835 per month,27·41 although the out-of-pocket cost borne by patients varies considerably by insurance formulary and coverage.”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [27]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“may reduce risk of cardiovascular events and death (35).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 1×
“first-line therapy hasbeneficial effects on A1C, weight, and cardiovascular mortality (36); there is little systematic data”
BackgroundThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“with type 1 diabetes (15,16), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (17).”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Cellular and Molecular Mechanisms of Metformin Action
LaMoia, T. E., & Shulman, G. I. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa023 · Cited by 791
The aetiology and molecular landscape of insulin resistance
James, D. E., Stöckli, J., & Birnbaum, M. J. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00390-6 · Cited by 690
Eberly, L. A., Yang, L., Eneanya, N. D., Essien, U., Julien, H., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., Giri, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6139 · Cited by 350
Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0864 · Cited by 346
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3494 · Cited by 285
Neuen, B. L., Oshima, M., Agarwal, R., Arnott, C., Cherney, D. Z., Edwards, R., Langkilde, A. M., Mahaffey, K. W., McGuire, D. K., Neal, B., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057736 · Cited by 290
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274
Pharmacological treatment of hyperglycemia in type 2 diabetes
Taylor, S. I., Yazdi, Z. S., & Beitelshees, A. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142243 · Cited by 245
Maida, C. D., Daidone, M., Pacinella, G., Norrito, R. L., Pinto, A., & Tuttolomondo, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042397 · Cited by 220
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
Cosentino, F., Cannon, C. P., Cherney, D. Z. I., Masiukiewicz, U., Pratley, R., Dagogo-Jack, S., Frederich, R., Charbonnel, B., Mancuso, J., Shih, W. J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050255 · Cited by 242
SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Talha, K. M., Anker, S. D., & Butler, J. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0030 · Cited by 185
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 181
Frias, J. P., Bonora, E., Nevarez Ruiz, L., Li, Y. G., Yu, Z., Milicevic, Z., Malik, R., Bethel, M. A., & Cox, D. A. (2021) · Diabetes Care · doi:10.2337/dc20-1473 · Cited by 199
Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications
Wysham, C., & Shubrook, J. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1771047 · Cited by 193
Liu, Y., Yu, Q., Luo, X., Yang, L., & Cui, Y. (2021) · Microsystems & Nanoengineering · doi:10.1038/s41378-021-00302-w · Cited by 182
Rubino, F., Cohen, R. V., Mingrone, G., le Roux, C. W., Mechanick, J. I., Arterburn, D. E., Vidal, J., Alberti, G., Amiel, S. A., Batterham, R. L., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30157-1 · Cited by 174
Insulin Resistance and Cancer: In Search for a Causal Link
Chiefari, E., Mirabelli, M., La Vignera, S., Tanyolaç, S., Foti, D. P., Aversa, A., & Brunetti, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011137 · Cited by 170
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 193
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-5938 · Cited by 163
Yamada, T., Wakabayashi, M., Bhalla, A., Chopra, N., Miyashita, H., Mikami, T., Ueyama, H., Fujisaki, T., Saigusa, Y., Yamaji, T., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01197-z · Cited by 159
Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09699-1 · Cited by 166
Schernthaner, G., Shehadeh, N., Ametov, A. S., Bazarova, A. V., Ebrahimi, F., Fasching, P., Janež, A., Kempler, P., Konrāde, I., Lalić, N. M., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01154-w · Cited by 164
Current and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 173
Glycemic variability and cardiovascular disease in patients with type 2 diabetes
Martinez, M., Santamarina, J., Pavesi, A., Musso, C., & Umpierrez, G. E. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002032 · Cited by 155
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Drugs · doi:10.1007/s40265-021-01499-w · Cited by 133
Dawed, A. Y., Mari, A., Brown, A., McDonald, T. J., Li, L., Wang, S., Hong, M.-G., Sharma, S., Robertson, N. R., Mahajan, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00340-0 · Cited by 131
Ganoderma lucidum : a comprehensive review of phytochemistry, efficacy, safety and clinical study
Wu, S., Zhang, S., Peng, B., Tan, D., Wu, M., Wei, J., Wang, Y., & Luo, H. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250051 · Cited by 159
Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139
Mirani, M., Favacchio, G., Carrone, F., Betella, N., Biamonte, E., Morenghi, E., Mazziotti, G., & Lania, A. G. (2020) · Diabetes Care · doi:10.2337/dc20-1340 · Cited by 146
Thethi, T. K., Pratley, R., & Meier, J. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14054 · Cited by 134
Understanding FAHFAs: From structure to metabolic regulation
Brejchová, K., Balas, L., Paluchová, V., Březinová, M., Durand, T., & Kuda, O. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101053 · Cited by 134
Risk factors for diabetic foot complications in type 2 diabetes—A systematic review
Rossboth, S., Lechleitner, M., & Oberaigner, W. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.175 · Cited by 165
Honigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., De Block, C., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 112
BAJAJ, H. S., Bergenstal, R. M., Christoffersen, A., Davies, M. J., Gowda, A., Isendahl, J., Lingvay, I., Senior, P. A., Silver, R., Trevisan, R., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2877 · Cited by 132
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes · doi:10.2337/dbi20-0040 · Cited by 123
Deng, X., Zhang, C., Wang, P., Wei, W., Shi, X., Wang, P., Yang, J., Wang, L., Tang, S., Fang, Y., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac210 · Cited by 126
Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review
Inaishi, J., & Saisho, Y. (2020) · Nutrients · doi:10.3390/nu12123846 · Cited by 107
Muscogiuri, G., Barrea, L., Faggiano, F., Maiorino, M. I., Parrillo, M., Pugliese, G., Ruggeri, R. M., Scarano, E., Savastano, S., Colao, A., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01574-9 · Cited by 128
Riddle, M. C., Philipson, L. H., Rich, S. S., Carlsson, A., Franks, P. W., Greeley, S. A. W., Nolan, J. J., Pearson, E. R., Zeitler, P. S., & Hattersley, A. T. (2020) · Diabetes Care · doi:10.2337/dci20-0065 · Cited by 117
Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 125
Mitochondrial Dysfunction in Cardiovascular Diseases: Potential Targets for Treatment
Yang, J., Guo, Q., Feng, X., Liu, Y., & Zhou, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.841523 · Cited by 114
“Further studies are valuable to investigate the effects of NR on CVDs and additional precursors of NAD+. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a standard treatment for type II diabetes due to their hypoglycemic effect and favorable safety in the clinic (Association, 2020).”
BackgroundManagement of diabetic ketoacidosis in adults: A narrative review
Elzouki, A.-N. Y., & Eledrisi, M. S. (2020) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_478_19 · Cited by 120
Tsai, C.-Y., Lu, H.-C., Chou, Y.-H., Liu, P.-Y., Chen, H.-Y., Huang, M.-C., Lin, C.-H., & Tsai, C.-N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.814770 · Cited by 92
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Management of Obesity in Adults with CKD
Friedman, A. N., Kaplan, L. M., le Roux, C. W., & Schauer, P. R. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020101472 · Cited by 94
Dave, C. V., Kim, S. C., Goldfine, A. B., Glynn, R. J., Tong, A., & Patorno, E. (2021) · Circulation · doi:10.1161/circulationaha.120.047965 · Cited by 92
Milenković, T., Bozhinovska, N., Μacut, D., Bjekić-Macut, J., Rahelić, D., Velija-Ašimi, Z., & Bureković, A. (2021) · Nutrients · doi:10.3390/nu13041307 · Cited by 119
Verma, S., McGuire, D. K., Bain, S. C., Bhatt, D. L., Leiter, L. A., Mazer, C. D., Monk Fries, T., Pratley, R. E., Rasmussen, S., Vrazic, H., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14160 · Cited by 89
Pelletier, R., Ng, K., Alkabbani, W., Labib, Y., Mourad, N., & Gamble, J. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098621989134 · Cited by 100
Boye, K., Ross, M., Mody, R., Konig, M., & Gelhorn, H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14244 · Cited by 88
Genetic risk converges on regulatory networks mediating early type 2 diabetes
Walker, J. T., Saunders, D. C., Rai, V., Chen, H., Orchard, P., Dai, C., Pettway, Y. D., Hopkirk, A. L., Reihsmann, C., Tao, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06693-2 · Cited by 93
Gabbay, R. A., Kendall, D., Beebe, C., Cuddeback, J., Hobbs, T., Khan, N. D., Leal, S., Miller, E., Novak, L. M., Rajpathak, S. N., et al. (2020) · Clinical Diabetes · doi:10.2337/cd20-0053 · Cited by 92
McCoy, R. G., Van Houten, H. K., Deng, Y., Mandic, P. K., Ross, J. S., Montori, V. M., & Shah, N. D. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.35792 · Cited by 89
Han, S. J., Ha, K. H., Lee, N., & Kim, D. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14261 · Cited by 86
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
Brunton, S. A., & Wysham, C. H. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798099 · Cited by 80
Szymczak-Pajor, I., Wenclewska, S., & Śliwińska, A. (2022) · Pharmaceuticals · doi:10.3390/ph15070810 · Cited by 101
Delineating mouse β-cell identity during lifetime and in diabetes with a single cell atlas
Hrovatin, K., Bastidas-Ponce, A., Bakhti, M., Zappia, L., Büttner, M., Salinno, C., Sterr, M., Böttcher, A., Migliorini, A., Lickert, H., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00876-x · Cited by 86
Cox, Z. L., Collins, S. P., Aaron, M. F., Hernandez, G. A., McRae, A. T., Davidson, B. T., Fowler, M. J., Lindsell, C. J., Harrell, F. E., Jenkins, C. A., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.10.071 · Cited by 92
Jardine, M., Kahleová, H., Levin, S., Ali, Z., Trapp, C., & Barnard, N. D. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab063 · Cited by 97
Management of Obesity in Cardiovascular Practice
Després, J.-P., Carpentier, A. C., Tchernof, A., Neeland, I. J., & Poirier, P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.035 · Cited by 87
SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort
Ata, F., Yousaf, Z., Khan, A. A., Razok, A., Akram, J., Ali, E. A. H., Abdalhadi, A., Ibrahim, D. A., Al Mohanadi, D. H. S. H., & Danjuma, M. I. (2021) · Scientific Reports · doi:10.1038/s41598-021-89752-w · Cited by 87
Koliaki, C. C., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00396-9 · Cited by 92
Le, P., Chaitoff, A., Misra-Hebert, A. D., Ye, W., Herman, W. H., & Rothberg, M. B. (2020) · Diabetes Care · doi:10.2337/dc19-2424 · Cited by 82
Kow, C. S., & Hasan, S. S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26498 · Cited by 85
Valenzuela Zamudio, F., & Segura Campos, M. R. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1857683 · Cited by 83
Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
Karwi, Q. G., Ho, K. L., Pherwani, S., Ketema, E. B., Sun, Q., & Lopaschuk, G. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab120 · Cited by 90
Lee, B., Lee, Y., Park, C., Rhee, E., Lee, W., Kim, N. H., Choi, K. M., Park, K., Choi, Y., Soo, B., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0010 · Cited by 86
Price, D. A., Deng, Q., Kipnes, M., & Beck, S. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01086-y · Cited by 77
Dougherty, J. A., Guirguis, E., & Thornby, K.-A. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020935105 · Cited by 75
The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk
Chan, S. W., Tomlinson, B., Chan, P., & Lam, C. W. K. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.1969413 · Cited by 89
“Up to now, more than 150 triterpenes have been identified from the spores, fruiting bodies, and mycelia of G. lucidum (Xia et al. 2014; Baby et al. 2015).”
BackgroundCernea, S., Dima, L., Correll, C. U., & Manu, P. (2020) · Drugs · doi:10.1007/s40265-020-01393-x · Cited by 84
Zeng, Z., Huang, S., & Sun, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00922-x · Cited by 78
Pharmacogenetics of Type 2 Diabetes—Progress and Prospects
Nasykhova, Y. A., Tonyan, Z. N., Mikhailova, A. A., Danilova, M. M., & Glotov, A. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186842 · Cited by 80
Weeda, E. R., Muraoka, A. K., Brock, M. D., & Cannon, J. M. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14060 · Cited by 73
Kalra, S., Das, A., Priya, G., Ghosh, S. K., Mehrotra, R., Das, S., Shah, P., Bajaj, S., Deshmukh, V. C., Sanyal, D., et al. (2020) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_843_20 · Cited by 84
Adherence and persistence rates of major antidiabetic medications: a review
Lee, D. S. U., & Lee, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00785-1 · Cited by 72
Uzoigwe, C., Liang, Y., Whitmire, S., & Paprocki, Y. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01053-7 · Cited by 62
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
Persson, F., Bain, S. C., Mosenzon, O., Heerspink, H. J. L., Mann, J. F. E., Pratley, R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1622 · Cited by 71
Reassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 63
Patoulias, D. I., Boulmpou, A., Teperikidis, E., Katsimardou, A., Siskos, F., Doumas, M., Papadopoulos, C. E., & Vassilikos, V. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i10.585 · Cited by 70
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
Giugliano, D., Longo, M., Caruso, P., Di Fraia, R., Scappaticcio, L., Gicchino, M., Petrizzo, M., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Diabetes Care · doi:10.2337/dc20-2623 · Cited by 69
Du, F., Liu, M., Wang, J., Hu, L., Zeng, D., Zhou, S., Zhang, L., Wang, M., Xu, X., Li, C., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155398 · Cited by 70
Bonora, E., Frias, J. P., Tinahones, F. J., Van, J., Malik, R. E., Yu, Z., Mody, R., Bethel, A., Kwan, A. Y. M., & Cox, D. A. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14465 · Cited by 67
Malik, M. E., Falkentoft, A. C., Jensen, J., Zahir, D., Parveen, S., Alhakak, A., Andersson, C., Petrie, M. C., Sattar, N., McMurray, J. J. V., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100617 · Cited by 67
Insulin Resistance Is Cheerfully Hitched with Hypertension
Sinha, S., & Haque, M. (2022) · Life · doi:10.3390/life12040564 · Cited by 85
Wan, C. C., Ouyang, J., Li, M., Rengasamy, K. R. R., & Liu, Z. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2157372 · Cited by 69
Shi, M., Zhang, H., Wang, W., Zhang, X., Liu, J., Wang, Q., Wang, Y., Zhang, C., Guo, X., Qiao, Q., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108610 · Cited by 67
Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes
Preiser, J., Provenzano, B. C., Wasineeart, M., Halenarova, K. W., & Cnop, M. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003237 · Cited by 69
Prattichizzo, F., de Candia, P., Nigris, V. D., Nicolucci, A., & Ceriello, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154308 · Cited by 70
Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis
Mirabelli, M., CHIEFARI, E. D., Puccio, L., FOTI, D. P., & Brunetti, A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103664 · Cited by 69
Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
Daza-Arnedo, R., Rico-Fontalvo, J.-E., Pájaro-Galvis, N., Leal-Martínez, V., Abuabara-Franco, E., Raad-Sarabia, M., Montejo-Hernández, J. D., Cardona-Blanco, M., Cabrales, J., Uparella-Gulfo, I., et al. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.07.007 · Cited by 68
GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery
Carullo, G., Mazzotta, S., Vega‐Holm, M., Iglesias‐Guerra, F., Vega‐Pérez, J. M., Aiello, F., & Brizzi, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01002 · Cited by 63
Harris, S. T., Patorno, E., Zhuo, M., Kim, S. C., & Paik, J. M. (2021) · Diabetes Care · doi:10.2337/dc21-0529 · Cited by 59
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S98-S110
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4246340431
- Cited by
- 914
- References
- 84
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 69 · 2023: 100 · 2022: 151 · 2021: 270 · 2020: 268
- FWCI
- 140.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Glycemic Control, Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Hypoglycemic Agents, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.